Damora Therapeutics (DMRA) Liabilities and Shareholders Equity (2019 - 2026)

Damora Therapeutics has reported Liabilities and Shareholders Equity for 8 years, with the latest figure at $535.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 3384.82% year-over-year to $535.4 million; the trailing twelve-month figure through Mar 2026 stood at $820.4 million (up 886.41% YoY), and the FY2025 full-year result was $260.5 million, up 1420.7% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $535.4 million, up from $260.5 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $535.4 million in Q1 2026, with the low at $10.7 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $88.5 million across 5 years, with a median of $50.0 million in 2023.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 55.18% — and 2026, when it soared 3384.82%.
• Damora Therapeutics' Liabilities and Shareholders Equity stood at $73.2 million in 2022, then sank by 47.77% to $38.2 million in 2023, then slumped by 55.18% to $17.1 million in 2024, then jumped by 1420.7% to $260.5 million in 2025, then jumped by 105.52% to $535.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $535.4 million (Q1 2026), $260.5 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.